Full-Time

Global Head

Multiple Teams

Updated on 8/23/2026

Deadline 9/4/26
GE Healthcare

GE Healthcare

1-10 employees

Imaging, monitoring, and healthcare IT solutions

Compensation Overview

$180k - $270k/yr

+ Performance-based cash bonus + Long-term incentives

No H1B Sponsorship

Remote in USA

Remote

Bachelor's

Category
Legal & Compliance (1)

Get referred to GE Healthcare

See people who can refer or advise you

Requirements
  • At least 10 years of experience leading global labeling in highly regulated pharmaceutical companies, including successful label negotiations and defense before the FDA, EMA, NMPA, and PMDA.
  • Strategic influence across Clinical, CMC, Medical, Market Access, and Commercial to shape development and lifecycle plans toward optimal labeling and access.
  • Deep expertise in Company Core Data Sheets, core/product information, and global/local labeling execution, with U.S. and European Union experience at minimum.
  • Exceptional negotiation and stakeholder management skills, internally and externally, with the ability to craft precise, defensible labeling language from clinical data.
  • Strong people leadership, including building high-performing teams, setting standards, and coaching labeling professionals and cross-functional contributors.
Responsibilities
  • Lead the global labeling strategy for all PDx products in development and on the market, aligning with target product profiles, target product labeling, and commercial strategies to enable optimal indications, claims, and competitive positioning.
  • Provide early, proactive feedback on Phase I–III and lifecycle-management clinical and CMC plans to shape endpoints, analyses, and evidence packages for labeling and access outcomes.
  • Chair the Global Labeling Committee and Labeling Working Groups, driving decisions, risk-benefit trade-offs, and cross-functional alignment.
  • Own Company Core Data Sheet creation, maintenance, and change control, and ensure timely, consistent rollout across the United States, European Union, China, Japan, and other markets.
  • Establish and track labeling key performance indicators, including cycle times, first-pass acceptance, variation closeout, and deviation rate, and drive continuous improvement across processes, templates, and training.
  • Serve as the principal labeling negotiator with the FDA, EMA and national competent authorities, China's NMPA, Japan's PMDA, and other authorities.
  • Lead labeling-focused meetings and written interactions to defend indications, populations, claims, dosing, warnings, and promotional language.
  • Anticipate and mitigate labeling risks that could lead to complete response letters, Risk Evaluation and Mitigation Strategies, postmarketing requirements, or postmarketing commitments, and escalate and resolve issues.
  • Partner with Market Access, Commercial, Medical, and Legal/Promotional Review to ensure label-to-launch readiness and compliant promotional scope aligned with positioning and payer needs.
  • Translate complex regulatory concepts into clear executive narratives and influence senior stakeholders on evidence, labeling, and go-to-market trade-offs.
  • Build and evolve the Global Labeling Center of Excellence, including governance, end-to-end processes, metrics, inspection readiness, and systems such as Veeva RIM and electronic product information.
  • Ensure audit and inspection readiness and robust documentation across labeling decisions, deviations, and exceptions.
  • Work with the Global Head of Regulatory Affairs, Advertising and Promotion, to provide overarching leadership, alignment, and governance for consistency among labeling, promotional claims, product positioning, market access needs, and global regulatory expectations.
Desired Qualifications
  • Hands-on experience with Veeva RIM and labeling systems, and understanding of electronic product information evolution.
  • Prior stewardship of a Global Labeling Committee or Working Group with measurable key performance indicator improvement.
  • An advanced degree in life sciences or pharmacy and literacy in Market Access to connect label language to reimbursement and promotional scope.

GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.

Company Size

1-10

Company Stage

IPO

Headquarters

Chicago, Illinois

Founded

1892

Get referred to GE Healthcare

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 orders rose 11.1% and backlog hit a record $23.9 billion.
  • August 3, 2026 Invenia ABUS Prime targets dense-breast screening demand and remote reading.
  • Tariff refunds and supply-chain shifts lifted Q2 2026 profits, while 2026 guidance stayed reaffirmed.

What critics are saying

  • Patient Care Solutions fell 13.5% in Q2 2026, and management is reviewing sale options.
  • CFO Jay Saccaro exits August 14, 2026, adding execution risk during the PCS review.
  • Siemens Healthineers and Philips pressure GEHC in imaging; stalled innovation erodes hospital preference.

What makes GE Healthcare unique

  • GE HealthCare combines imaging, pharmaceutical diagnostics, and MIM software across one workflow stack.
  • Its August 2026 ABUS Prime and Allia upgrades monetize installed bases without replacements.
  • FDA-cleared AI tools like ProtégéAI+ 2.0 shorten oncology workflows and deepen switching costs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Tuition Reimbursement

Relocation Assistance

Company News

Yahoo Finance
Aug 3rd, 2026
GE HealthCare launches Invenia ABUS Prime and StreamVue for breast cancer screening

GE HealthCare has launched Invenia ABUS Prime and ABUS StreamVue, expanding its breast imaging portfolio with solutions for supplemental screening in women with dense breasts. The Invenia ABUS Prime system has been installed at BeSound in Los Angeles, marking one of the first US installations. ABUS StreamVue is a browser-based reading solution enabling remote exam review across imaging networks. The system received FDA 510(k) clearance and CE Marking. Studies show 40% of women have dense breasts, carrying four to six times higher breast cancer risk. Research indicates mammography may miss one-third of cancers in dense breasts. Invenia ABUS Prime features AI-enabled tools including Scan Quality Assessment and can increase scan speed by up to 40%. The AI Assistant has demonstrated a 33% reduction in reading time.

Yahoo Finance
Jul 29th, 2026
GE HealthCare Q2: Orders up 11%, backlog hits record $23.9B amid Patient Care struggles

GE HealthCare Technologies reported second-quarter results with orders rising 11% year-over-year and backlog reaching a record $23.9 billion. Revenue grew 3.5% organically to $5.3 billion, driven by Advanced Imaging Solutions and Pharmaceutical Diagnostics, which posted organic growth of 5% and 14.6% respectively. Patient Care Solutions remained weak, with revenue falling 13.5% due to component shortages and fulfilment problems. Management is reviewing strategic options for the segment, including a potential sale. The company maintained its full-year outlook of 3–4% organic sales growth, adjusted earnings per share of $4.80–$5.00, and approximately $1.6 billion in free cash flow. CFO Jay Saccaro is departing, with George Newcomb serving as interim CFO.

Yahoo Finance
Jul 29th, 2026
GE HealthCare beats profit estimates on imaging demand and $129M tariff refunds

GE HealthCare exceeded Wall Street's second-quarter profit estimates, driven by robust demand for diagnostic and imaging devices and tariff refunds from the Trump administration. The medical device maker reported net income of $561 million, up from $486 million last year, which included $129 million in tariff refunds. Revenue reached $5.30 billion for the quarter ending 30 June, surpassing the estimated $5.26 billion. Sales in imaging devices grew 7.9%, whilst pharmaceutical diagnostics jumped 15.6%. Adjusted earnings per share came in at $1.13, beating analysts' estimate of $1.04. The company's shares rose 12% in premarket trading. However, GE HealthCare noted that geopolitical instability, including Middle East conflicts, negatively affected costs, supply chains and logistics during the quarter.

Yahoo Finance
Jul 29th, 2026
GE HealthCare beats estimates with record orders, shares jump 9%

GE HealthCare Technologies reported second-quarter results that exceeded Wall Street expectations. Adjusted earnings per share reached $1.13, beating the $1.04 consensus estimate, whilst revenue hit $5.3 billion, surpassing the $5.26 billion forecast and marking a 5.7% year-on-year increase. The company delivered record organic orders growth of 11.1% with a book-to-bill ratio of 1.15 times and backlog of $23.9 billion. Organic revenue grew 3.5%, driven by strength in Pharmaceutical Diagnostics and Advanced Imaging Solutions. Patient Care Solutions revenue declined 13.5% year-on-year. Adjusted EBIT margin came in at 14.2%, down 40 basis points from the prior year. Shares jumped 9% premarket following the release. GE HealthCare reaffirmed its full-year guidance, projecting organic revenue growth of 3.0% to 4.0% and adjusted EPS between $4.80 and $5.00.

Fortune
Jul 23rd, 2026
GE's $593B comeback: How CEO Larry Culp pulled off history's greatest turnaround

GE CEO Larry Culp has orchestrated what many industry leaders consider the greatest corporate turnaround in modern business history. When he took over in 2018, GE's market capitalisation stood at $96 billion, down over 80% from its 2000 peak, with $150 billion in crushing debt. Today, the three companies Culp created from GE's breakup — GE Aerospace, GE Vernova, and GE HealthCare — have a combined market value of $689 billion. The trio has delivered annualised returns of roughly 30% since Culp's arrival, double the S&P 500's performance. GE Vernova has jumped over 600% whilst GE Aerospace has risen more than 160%. Culp's approach centred on lean manufacturing principles learnt from the Toyota Production System. He decentralised operations, eliminated three-quarters of central staff positions, and fostered a culture encouraging managers to spotlight problems rather than successes.